Marian Fedor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marian Fedor has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
F. Kovář
Clinic of Internal Medicine I., Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital Martin, Slovakia
1 shared publicationFrantisek Kovar
1 shared publicationI. Škorňová
Clinic of Hematology and Blood Transfusion, National Centre of Hemostasis and Thrombosis, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital Martin, Slovakia
1 shared publicationIngrid Skornova
1 shared publicationJ. Fedorová
Hemo-Medika s.r.o., Centre of Hemostasis and Thrombosis, Martin, Slovakia
1 shared publicationJ. Staško
Clinic of Hematology and Blood Transfusion, National Centre of Hemostasis and Thrombosis, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital Martin, Slovakia
1 shared publication
Latest Publications
- 2 July 2014
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 21 (4) , 334-338
Monitoring the Efficacy of ADP Inhibitor Treatment in Patients With Acute STEMI Post-PCI by VASP-P Flow Cytometry Assay
Introduction: Dual antiplatelet treatment (DAPT) with clopidogrel and aspirin represents common approach in prevention of thromboembolic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI). The drawback of clopidogrel treatment is large interindividual variability in response. Aim: Our article aims to suggesting the most convenient method in monitoring the DAPT of post-PCI patients. Methods: We analyzed the on-treatment platelet reactivity by light transmission aggregometry and vasodilator-stimulated phosphoprotein (VASP) flow cytometric assay. Samples were obtained in 3 intervals: first prior to PCI, then 1, and 30 days after PCI. Results: Based on VASP-platelet reactivity index (PRI), we observed 100% response rate in prasugrel-treated patients and 62% to 73 % in the clopidogrel group. Overall, only 2 (7%) patients with the VASP-PRI value in therapeutic range had major adverse cardiovascular events. Conclusion: Our results hint VASP-phosphorylation assay as a relevant method for guiding and tailoring DAPT.
- 2 July 2014
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 21 (4) , 334-338
Monitoring the Efficacy of ADP Inhibitor Treatment in Patients With Acute STEMI Post-PCI by VASP-P Flow Cytometry Assay
Introduction: Dual antiplatelet treatment (DAPT) with clopidogrel and aspirin represents common approach in prevention of thromboembolic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI). The drawback of clopidogrel treatment is large interindividual variability in response. Aim: Our article aims to suggesting the most convenient method in monitoring the DAPT of post-PCI patients. Methods: We analyzed the on-treatment platelet reactivity by light transmission aggregometry and vasodilator-stimulated phosphoprotein (VASP) flow cytometric assay. Samples were obtained in 3 intervals: first prior to PCI, then 1, and 30 days after PCI. Results: Based on VASP-platelet reactivity index (PRI), we observed 100% response rate in prasugrel-treated patients and 62% to 73 % in the clopidogrel group. Overall, only 2 (7%) patients with the VASP-PRI value in therapeutic range had major adverse cardiovascular events. Conclusion: Our results hint VASP-phosphorylation assay as a relevant method for guiding and tailoring DAPT.
- 23 September 2013
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 8 (9) , 278
Dual antiplatelet treatment in patients with acute ST-elevation myocardial infarction — is it always sufficiently effective?
- 23 September 2013
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 8 (9) , 278
Dual antiplatelet treatment in patients with acute ST-elevation myocardial infarction — is it always sufficiently effective?